Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody

Blood

Volumn 89, Issue 9, 1997, Pages 3287-3295

  Moulian, Nathalie ^a,b,c   Bidault, Jocelyne ^a,b,c   Truffault, Frédérique ^a,b,c   Yamamoto, Ana Maria ^a,b,c   Levasseur, Philippe ^a,b,c   Berrih Aknin, Sonia ^a,b,c  

^a CNRS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHOLINERGIC RECEPTOR; FAS ANTIGEN; RECEPTOR ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYASTHENIA GRAVIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCHOOL CHILD; THYMOCYTE;

EID: 0030911161     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3287     Document Type: Article

References (53)

1. Lindstrom JM, Seybold ML, Lennon VA, Whittingham S, Duane DD: Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology (Minneap) 26:1054, 1976
2. Berrih-Aknin S, Morel E, Raimond F, Safar D, Gaud C, Binet JP, Levasseur P, Bach JP: The role of the thymus in myasthenia gravis. Immunohistological and immunological studies in 115 cases. Ann NY Acad Sci 505:50, 1987
3. Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF: Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurol 34:66, 1984
4. Mulder DG, Graves M, Herrmann C: Thymectomy for myasthenia gravis: Recent observations and comparisons with past experience. Ann Thorac Surg 48:551, 1989
5. Molnar J, Szobor A: Myasthenia gravis: Effect of thymectomy in 425 patients. A 15-year experience. Eur J Cardiothorac Surg 4:8, 1990
6. Kuks JB, Oosterhuis HJ, Limburg PC, The TH: Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmunity 4:197, 1991
7. Kuks JB, Oosterhuis HJ, Limburg PC, The TH: Antibodies to acetylcholine receptors in myasthenia gravis. In vitro synthesis by peripheral blood lymphocytes before and after thymectomy. Clin Exp Immunol 87:246, 1992
8. Willcox N, Newsom-Davis J, Calder LR: Cell types for antiacetylcholine receptor antibody by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clin Exp Immunol 58:97, 1984
9. Safar D, Berrih-Aknin S, Morel E: In vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: Correlation with thymic histology and thymic epithelial-cell interactions. J Clin Immunol 7:225, 1987
10. Melms AS, Chreste BCG, Schalke H, Wekerle H, Mauron A, Ballivet M, Barkas T: Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 83:785, 1989
11. Sommer N, Willcox N, Harcourt GC, Newsom-Davies J: Myasthenie thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 28:312, 1990
12. Cohen-Kaminsky S, Levasseur P, Binet JP, Berrih-Aknin S: Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: Possible role in autoimmune pathogenesis. J Neuroimmunol 24:75, 1989
13. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, Vernet der Garabedian B, Treton D, Galanaud P, Richard Y: Thymic B cells from myasthenia gravis patients are activated B cells: Phenotypic and functional analysis. J Immunol 145:2115, 1990
14. Von Boehmer H: The selection of α-β heterodimeric T cell receptor for antigen. Immunol Today 7:333, 1986
15. Surh CD, Sprent J: T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100, 1994
16. Nossal GJV: Negative selection of lymphocytes. Cell 76:229, 1994
17. Webb S, Morris C, Sprent J: Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity. Cell 63:1249, 1990
18. Nagata S, Suda T: Fas and Fas ligand: Ipr and gld mutations. Immunol Today 16:39, 1995
19. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1994
20. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93:1029, 1994
21. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwasaki S: Expression and function of Fas antigen and bcl-2 in human systemic erythematosus lymphocytes. Clin Immunol Immunopathol 73:109, 1994
22. Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, Nakabayashi T, Tsutsumi A, Fujisaku A, Koike T: Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patient with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia. Clin Exp Immunol 99:245, 1995
23. Fisher GH, Rosenberg FJ, Staus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell 81:935, 1995
24. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts LAG, Debatin KM, Fisher A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347, 1995
25. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
26. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-l/(Fas/CD95). Nature 373:438, 1995
27. Brunner T, Mogil RG, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CH, Green DR: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441, 1995
28. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444, 1995
29. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
30. Singer GG, Abbas AK: The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365, 1994
31. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H, Ogasawara J, Tanaka T, Yoshida N, Nagata S: Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 93:2131, 1996
32. Zhou T, Bluethmann H, Eldridge J, Berry K, Mountz JD: Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. J Immunol 8:3651, 1993
33. Mariani SM, Matiba B, Armandola EA, Krammer PH: The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice. Eur J Immunol 24:3119, 1994
34. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 181:485, 1995
35. Fisher GH, Lenardo MJ, Zuniga-Pflucker JC: Synergy between T cell receptor and Fas (CD95/APO-1) signaling in mouse thymocyte death. Cell Immunol 169:99, 1996
36. Levine G, Rosai J: Thymic hyperplasia and neoplasia: A review of current concepts. Hum Pathol 9:495, 1978
37. Lindstrom J: An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 7:36, 1977
38. Voltz R, Hohlfeld R, Fateh-Moghadam A, Wilt TN, Wick M, Reimers C, Siegele B, Wekerle H: Myasthenia gravis: Measurement of anti-AChR autoantibodies using cell line TE671. Neurology 41:1836, 1991
39. Berrih-Aknin S, Cohen-Kaminsky S, Truffault T: T-cell receptor expression in the thymus from patients with myasthenia gravis. Ann NY Acad Sci 756:438, 1995
40. Debatin KM, Suss D, Krammer PH: Differential expression of APO-1 on human thymocytes: Implications for negative selection? Eur J Immunol 24:753, 1994
41. Truffault T, Cohen-Kaminsky S, Khalil I, Levasseur P, Ber-rih-Aknin S: Altered intrathymic T cell repertoire in human myasthenia gravis. Ann Neurol February 1997 (in press)
42. Bemh-Aknin S, Cohen-Kaminsky S, Lepage V, Neumann D, Bach JF, Fuchs S: T-cell antigenic sites involved in myasthenia gravis: Correlations with antibody titre and disease severity. J Autoimmunity 4:137, 1991
43. Klas C, Debatin KM, Jonker RR, Krammer PH: Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5:625, 1993
44. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N: Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 149:3753, 1992
45. Yonehara S, Nishimura Y, Kishil S, Yonehara M, Takazawa K, Tamatani T, Ishii A: Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol 6:1849, 1994
46. Masunaga A, Arai T, Yoshitake T, Hoyama S, Sugawara I: Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis. Immunol Lett 39:169, 1994
47. Agus DB, Surh CD, Sprent J: Reentry of T cells to the adult thymus is restricted to activated T cells. J Exp Med 173:1039, 1991
48. Owen-Schaub LB, Yonehara S, Crump III WL, Grimm EA: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 140:197, 1992
49. Emilie D, Crevon MC, Cohen-Kaminsky S, Peuchmaur M, Devergne O, Berrih-Aknin S, Galanaud P: In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Hum Pathol 22:461, 1991
50. Lalor DJ, Hayashi J: Expression of Fas ligand by thymic epithelial cells. The 9th International Congress of Immunology. San Francisco, CA, 1995, p 743 (abstr)
51. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB: Levels of soluble Fas/APO-l/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735, 1995
52. Goel N, Ulrich DT, StCIair EW, Fleming JA, Lynch DH, Seidin MF: Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease. Arthritis Rheum 38:1738, 1995
53. Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC: T helper type l/T helper type 2 cytokines and T cell death: Preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 182:1759, 1995